THERAKOS™ Photopheresis is indicated for the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma that are unresponsive to other forms of treatment.
THERAKOS™ Photopheresis has been used as a palliative therapy for CTCL for over 20 years, in over 500,000 treatments.
THERAKOS™ Photopheresis has demonstrated efficacy and safety in CTCL patients has not been associated with secondary malignancies or opportunistic infections.3,5
Extracorporeal photopheresis (ECP) is performed using either the THERAKOS™ CELLEX® Photopheresis System or the THERAKOS™ UVAR XTS® Photopheresis System.
Specially designed for medical professionals to use in their practice.
Sherry's Experience
The Caregiver's Perspective
The Long Journey
About THERAKOS™ Photopheresis Treatment
How THERAKOS™ Photopheresis Works
See top Opinion Leaders address FAQs about THERAKOS™ Photopheresis
Indications
Methoxsalen Sterile Solution is indicated for extracorporeal administration with the THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment.
Methoxsalen should be used only by physicians who have special training in the THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis Systems. Methoxsalen is contraindicated in patients exhibiting idiosyncratic reactions to psoralen compounds, patients with a specific history of a light sensitive disease, or patients with aphakia.
THERAKOS™ Photopheresis is not appropriate for patients who cannot tolerate extracorporeal volume loss or shifts, or patients with coagulation disorders. See Important Safety Information for additional details.
